Pacific Biosciences (NASDAQ:PACB) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.4, a high estimate of $12.00, and a low estimate of $2.00. Experiencing a 50.56% decline, the current average is now lower than the previous average price target of $8.90.

Interpreting Analyst Ratings: A Closer Look

A comprehensive examination of how financial experts perceive Pacific Biosciences...